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Abstract
CAPN3 mutations cause a limb girdle muscular dystrophy. Functional charac-
terization of novel mutations facilitates diagnosis of future cases. We have iden-
tified a novel (c.1992 + 2T>G) CAPN3 mutation that disrupts the donor splice
site of intron 17 splicing out exon 17, with mRNA levels severely reduced or
undetectable. The mutation induces a strong change in the 3D structure of the
mRNA which supports no-go mRNA decay as the probable mechanism for
RNA degradation. The mutation was identified in two unrelated Roma individ-
uals showing a common ancestral origin and founder effect. This is the first
Roma CAPN3 mutation to be reported.
Introduction
The Roma population is the most numerous ethnic
minority in Europe. A small number of ancestors, subse-
quent endogamy, and population fissions causing sec-
ondary founder effects explain the increased frequency of
Mendelian disorders in this population.1–5 Founder muta-
tions are often found to cause 100% of the cases of a
specific disease in this population group,6,7 with impor-
tant implications for diagnosis. Several neuromuscular
disorders are particularly frequent among the Roma.7–9
The identification of founder mutations would allow a
rapid diagnosis and prevention of future cases in this
population group through genetic counselling.
CAPN3 encodes a calcium modulated nonlysosomal
protease predominantly expressed in skeletal muscle.10
Limb girdle muscle dystrophy 2A (LGMD2A), due to
CAPN3 mutations is one of the most frequent muscular
dystrophies, however, its presence in the Roma popula-
tion has not been reported before. Different mutation
types have been reported in CAPN3, including splice site
mutations.12 Here, we describe a novel intronic mutation
2328 ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited.
that causes exclusion of exon 17 and RNA mediated
decay.
Patients and Methods
Subjects of study
Findings from two nonrelated Iberian Roma subjects
from Andalusia (Spain) are reported. The study was
approved by the local Ethics Committee at Hospital
Universitario Virgen del Rocıo. Informed consent was
obtained from the legal representative.
Muscle histology
Muscle samples were obtained by open biopsy from both
patients and processed following standard procedures.
Usual stains for muscle and routine immunohistochemi-
cal stainnings (IHC) including utrofin (Novocastra Ref.
DRP3/20C5), and calpain-3 (Leica NCL-CALP-2C4 and
Leica NCL-CALP-12A2) were performed.
Western blot analysis
Protein lysates from muscle were resolved on 10% SDS–
PAGE gels and transferred to PDVF membranes. Full size
calpain-3 and autolytic fragments were detected with the
above described antibodies. Rabbit anti-GAPDH (Sigma-
Aldrich, Ref. G9545) was developed as load control.
CAPN3 genetic screening
DNA was extracted from blood and screened by Sanger
sequencing of the 24 exons and the flanking sequence of
each intron of CAPN3 (ABI3730 DNA Sequencer).
Next generation sequencing
Targeted next generation sequencing of 106 neuromuscu-
lar disease genes, including 15 LGMD genes, 12 distal
myopathy genes and 52 CMT genes was performed (Illu-
mina) on both patients. To cover other genes of interest,
exome sequencing was performed on patient 1 with a
median coverage of 100x (Illumina) and genes included
in GeneTable 2018 (www.musclegenetable.fr) were
screened for pathogenic variants.
Transcript analysis
RNA was extracted from frozen muscle (RNA purifica-
tion kit Norgen, Ref.17200). Integrity of RNA was
checked using the Agilent 2100 BioAnalyzer system. Pri-
meScriptTM RT Master Mix kit (Takara, Ref. RR036A)
was used to obtain cDNA. CAPN3 cDNA was amplified
by PCR. DES and DAG1 cDNA was also amplified as
controls. CAPN3 cDNA PCR products were sequenced
by Sanger method.
Haplotype analysis
Relatedness of the two cases was studied by haplotype
analysis. The two affected individuals and parents of
Patient 2 were included in the analysis. No first-degree
relatives of Patient 1 were available. Six microsatellite
markers spanning 13 Mb around CAPN3 were amplified
by PCR using fluorescently labeled forward primers. PCR
products were analyzed in an ABI3500 Genetic Analyzer
and their sizes were estimated using GeneMapper software
4.1. Additionally, five single nucleotide polymorphisms
with minor allele frequency close to 50% were analyzed
by Sanger sequencing.
Results
Clinical findings
Patient 1 was born to consanguineous parents. She was
first investigated at the age of 13 after an incidental find-
ing of high levels of serum CK (8900 IU/L). When asked,
she reported low performance on sports and motor activi-
ties for the last year. Examination at age 13 showed mild
proximal lower limb weakness and hypoactive deep ten-
don reflexes. She later developed difficulty to climb stairs
and to run. Last examination at age 15 showed asymmet-
ric scapular winging, weakness of wrist and finger exten-
sors, and interossei and proximal lower limb weakness. A
muscle MRI performed at age 13 showed mild fat infiltra-
tion of posterior compartment of thighs (Fig. 1A). Patient
2 was born to consanguineous parents. He presented at
age 8 years after finding a serum CK of 3700 IU/L. He
reported muscle cramps when playing sports as the only
muscle symptom. At age 10 he was found to have mild
proximal upper and lower limb weakness. Last examina-
tion at age 12 revealed bilateral scapular winging and
waddling gate. He could stand from a seat but needed
support to stand from a squat. There was weakness of
deltoids, biceps, glutei, tibialis anterior, and adductor hal-
lucis longus, being able to walk on his toes but not on
his heels.
Muscle histopathology
Muscle biopsies were performed at age 13 in Patient 1
and at age 10 in Patient 2. Both showed a mild dys-
trophic pattern, absence/deficiency of calpain-3, and over-
expression of utrophin (Fig. 1B).
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Immunoblot
Immunoblot performed on muscle tissue showed absence
of the full-length form of calpain-3 in muscle from
Patient 1, and severe reduction in Patient 2. Absence of
autocatalytic forms was found in both patients (Fig. 1C).
Genetic screening
Sanger sequencing of CAPN3 identified an intronic
homozygous NM_000070.2 c.1992 + 2T>G variant in
both patients (Fig. 2A). Accordingly, parents of Patient 2
were heterozygous carriers. Targeted NGS performed in
Patients 1 and 2 and exome sequencing in Patient 1
confirmed the presence of a homozygous CAPN3
c.1992 + 2T>G variant and did not identify pathogenic
variants in genes related with other neuromuscular dis-
ease. The CAPN3 c.1992 + 2T>G variant is not present in
databases of normal controls (gnomAD).11 Screening of
whole exome sequencing data from 50 Roma controls did
not identify any carriers. The variant involves the second
position of the canonical donor splice site (GT) of intron
17, is predicted to be damaging by DANN,12 Muta-
tionTaster13 and FATHMM-MKL14 and to break the
donor splice site by SSPP analysis NetGene2.15 A patho-
genic T> A variant at the same c.1992 + 2 position has
been reported, although no characterization is available
(https://www.ncbi.nlm.nih.gov/clinvar/variation/596001/).
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Figure 1. Muscle MRI, muscle biopsy, CAPN3 immunoblot and RT-PCR in patients homozygous for CAPN3 c.1992 + 2T>G. (A) Muscle MRI of
Patient 1 showed mild fat infiltration of posterior compartment of thigh. (B) Muscle biopsy: H&E and immunohistochemical staining for calpain-3
(2C4 antibody) and utrophin in a control, Patient 1 and Patient 2. Mild dystrophic pattern and a complete absence of immunoreactivity for
calpain-3 were present in both cases. Utrophin immunostaining showed a moderate overexpression compared with control muscle. (C)
Immunoblot in muscle tissue of Patient 1 (P1) shows complete absence of the full-size form as well as autocatalitic forms of Calpain-3. In Patient
2 (P2), full-size form is reduced and in both autocatalytic forms are absent, compared with Controls (Ctr). CtrP1 and CtrP2: LGMD2A disease
controls (D) RT-PCR of exons 11-21 of CAPN3 cDNA from muscle tissue: No amplification was observed in Patient 1 (P1) and a faint band of
slightly reduced molecular weight was obtained in Patient 2 (P2). RT-PCR of control cDNAs were successfully amplified in all samples. RNA
integrity numbers (RIN) obtained for the RNA samples were 8.3 (Crt1), 7.3 (Ctr2), 8.7 (P1), and 6.8 (P2).
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Figure 2. Molecular characterization of the CAPN3 c.1992 + 2T>G variant. (A) Sanger sequencing of genomic DNA of Patient 1 showing a
homozygous nucleotide substitution T to G at position + 2 of intron 17 (B) Sanger sequencing of exons 11-21 of cDNA from muscle showing
skipping of exon 17. (C, D, E) Structural changes induced in the CAPN3 c.1992 + 2T> G mRNA molecule. (C) Predicted full-length wild-type
CAPN3 mRNA structure. Exon 17 is marked in red. The black box highlights the region of the mRNA that harbors the structural changes. (D, E)
Magnification of the region showing of the structural change of the mRNA molecule. (D) Wild-type CAPN3 mRNA and (E) c.1992 + 2T>G CAPN3
mRNA . (F) Haplotype analysis showing a shared area of homozygosity and common haplotype around the position of CAPN3. Microsatellite
markers and single nucleotides polymorphisms used for the analysis are shown. (G) Diagram of chromosome 15 showing the region studied
including the position of the markers used. Position of CAPN3 is marked in a green box. Microsatellite markers positions are highlighted in red
and single nucleotide polymorphisms in blue.
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RNA analysis
To investigate whether the c.1992 + 2T>G variant affects
splicing, total muscle RNA was retrotranscribed to cDNA
and amplified. No CAPN3 cDNA was detected in Patient
1. In Patient 2, severely reduced levels were observed.
Sanger sequencing of cDNA in Patient 2 revealed skipping
of exon 17 (Fig. 2B), predicted to cause a 25 amino-acid
in-frame deletion. PCR amplification of control cDNAs
expressed in muscle (DES and DAG1) was efficient in
patients and controls (Fig. 1D).
RNAfold program (Vienna RNA package)16 analysis of
the mutant RNA molecule predicted the introduction of
strong secondary structure changes involving a large part
of the molecule (Fig. 2C–E).
Haplotype analysis
To investigate whether the identified mutation has a com-
mon ancestral origin in the two families we analysed the
genotype of 11 markers spanning 13Mb which identified
an area of at least 6.2Mb of homozygosity and common
haplotype, around the position of the mutation, shared
by the two patients, revealing a common ancestor and a
founder effect (Fig. 2F–G).
Discussion
Here, we report a novel Roma mutation causing LGMD.
This is, to our knowledge, the first CAPN3 mutation
reported in the Roma population. The mutation, identi-
fied in apparently unrelated patients, has a common
ancestor supporting the notion that this is a Roma foun-
der mutation. Analysis of subsequent cases would be nec-
essary to corroborate this founder effect.
Our patients displayed distal weakness from early in
disease course. The clinical presentation of CAPN3 muta-
tions is highly variable, including asymptomatic
HyperCK, pelvic girdle weakness and scapulohumeral
weakness.17 Distal muscle involvement, although rare,
have been previously described.18,19 However, to our
knowledge, involvement of distal upper limb muscles at
early stages has not been documented before. Other intro-
nic mutations in CAPN3 have previously been reported
causing abnormal splicing,20,21 including a c.1992 + 1
G> T CAPN3 variant that lies on a base next to our novel
mutation.22,23 The c.1992 + 1 G> T CAPN3 mutation
abolishes the canonical donor splice site of exon 17, caus-
ing skipping of exon 17 or inclusion of 31bp of intron 17
resulting in very low or undetectable levels of muscle
CAPN3 RNA and protein,22,23 in line with our results.
RNA quality control systems identify and degrade aber-
rant mRNAs through different mRNA surveillance
pathways.24 Non-sense25,26 and non-stop19 mediated
decay (NMD, NSD) are mechanisms to trigger RNA
degradation. The most recently known RNA surveillance
mechanism is No-Go Decay (NGD), in which aberrant
secondary structures causing stalls in translation elonga-
tion trigger mRNA endonucleolytic cleavage.27 NGD has
been described as the pathogenic mechanism in other
splice site mutation, causing human disease.28
Different levels of protein detected by immunoblot
among patients with the same CAPN3 mutation have pre-
viously been described,29 however, it is interesting that in
our report, different protein and RNA levels are seen in
patients of the same background, both being equally clini-
cally affected from a young age and sharing a characteris-
tic phenotype with distal involvement. The different RNA
and protein levels observed may represent unequal effi-
ciency in the RNA degradation mechanisms, which are
not completely understood.
We have shown how the CAPN3 c.1992 + 2T>G
induces structural changes in the mutant RNA. These
profound structural alterations of the mRNA molecule
may cause stalls during translation and elongation. In our
patients, RNA is severely reduced or absent. These find-
ings are in keeping with no-go mediated decay as a novel
pathogenic mechanism in calpainopathies.
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